PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum PL 12063/0133-0134 1 Public Assessment Report UKPAR Galpharm Nicotine Replace 2 mg and 4 mg Gum (Nicotine resinate) UK Licence No: PL 12063/0133-0134 Wrafton Laboratories Limited
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
1
Public Assessment Report
UKPAR
Galpharm Nicotine Replace 2 mg and 4 mg Gum
(Nicotine resinate)
UK Licence No: PL 12063/0133-0134
Wrafton Laboratories Limited
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
2
LAY SUMMARY Galpharm Nicotine Replace 2 mg and 4 mg Gum
(Nicotine resinate)
This is a summary of the Public Assessment Report (PAR) for Galpharm Nicotine Replace 2 mg and 4
mg Gum (PL 12063/0133-0134). These medicinal products will be referred to as Nicotine Gum in the
remainder of this summary, for ease of reading.
This summary explains how Nicotine Gum was assessed and its authorisation recommended, as well as
its conditions of use. It is not intended to provide practical advice on how to use Nicotine Gum.
For practical information about using Nicotine Gum, patients should read the package leaflets or contact
their doctor or pharmacist.
What is Nicotine Gum and what is it used for?
Nicotine Gum is a ‘generic medicine’. This means that Nicotine Gum is similar to ‘reference medicines’
authorised in the European Union (EU) called Nicorette 2 mg and 4 mg Freshmint Gum (McNeil
Products Ltd).
Nicotine Gum can reduce the urge to smoke by providing some of the nicotine previously inhaled from
cigarettes. This type of treatment is called Nicotine Replacement Therapy (NRT).
Nicotine Gum can be used to stop smoking completely by replacing all of the cigarettes smoked.
However, it can also be used to help:
• cut down the number of cigarettes smokers smoke, for example, if smokers are unable to stop smoking
completely or want to replace certain cigarettes
• in situations where smokers do not wish to smoke to avoid harming others, such as children or family
• in situations where smokers are unable to smoke, such as at work or on public transport.
If possible, when giving up smoking, this medicated chewing gum should be used with a stop smoking
behavioural support programme which will increase the chances of success.
Nicotine Gum can also be used to help pregnant or breast-feeding women to stop smoking. Using NRT
is safer for women and their baby than continuing to smoke.
It is always better to stop smoking completely. Smoking is harmful and has no health benefits. NRT
products like this medicated chewing gum can help smokers stop smoking. Any risks or possible side
effects from NRT are much less than the proven dangers of continuing to smoke, because the chewing
gum does not contain the tar, carbon monoxide or other toxic chemicals in cigarette smoke. Some people
worry that, when they have stopped smoking, they may become dependent on NRT instead. This is very
rare, and if it were to happen it is still safer than continuing to smoke. It is also an easier habit to break.
How does Nicotine Gum work?
Nicotine Gum contains nicotine resin which when chewed, releases nicotine which is absorbed through
the lining of the mouth. This nicotine relieves some of the cravings and unpleasant withdrawal
symptoms, such as feeling ill, anxious and irritable, that smokers frequently feel when they try to give up
smoking or cut down the number of cigarettes smoked.
How is Nicotine Gum used?
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
3
This is a special type of gum and is not like ordinary chewing gum. Smokers should chew 1 piece of
medicated chewing gum for about 30 minutes with regular pauses. It is important to chew the medicated
chewing gum slowly and with regular pauses to allow the nicotine to be taken in through the lining of
the mouth, and also so that the nicotine is not released too quickly. The chewing gum must be disposed
carefully after 30 minutes.
The following instructions for use depend on whether smokers are stopping smoking completely, cutting
down the number of cigarettes they smoke per day or if smokers are going without cigarettes for a short
time
The 2 mg chewing gums are suitable for people who smoke 20 or fewer cigarettes per day, or by
people who are heavier smokers who are reducing the number and strength of the product they
are using.
The 4mg chewing gums are suitable for people who smoke 20 or more cigarettes per day.
The chewing gum may not be suitable for use if smokers have false teeth, as it could stick to
them and more rarely, damage the dentures.
The recommended dose of gums in adults and young people aged 12 years and over who smoke 20
cigarettes or less is one 2mg gum, as required, to manage cravings. Smokers should not use more than
one piece of chewing gum at a time and must not exceed more than 15 gums per day.
The recommended dose of gums in adults and young people aged 12 years and over who smoke 20
cigarettes or more is one 4mg gum as required to manage cravings. Smokers should not use more than
one piece of chewing gum at a time and must not exceed more than 15 gums per day.
Nicotine Gum is a General Sale List (GSL) medicine
For further information on how Nicotine Gum is used, refer to the Summaries of Product Characteristics
or package leaflets available on the MHRA website.
What benefits of Nicotine Gum have been shown in studies?
As Nicotine Gum is a generic medicine, studies have been limited to tests to determine that it is
bioequivalent to the reference products, Nicorette 2 mg and 4 mg Freshmint Gum (McNeil Products
Ltd). Two medicines are bioequivalent when they produce the same levels of the active substance in the
body.
What are the possible side effects of Nicotine Gum?
Because Nicotine Gum is a generic medicine and is bioequivalent to Nicorette 2 mg and 4 mg Freshmint
Gum, its benefits and possible side effects are taken as being the same as those of the reference
medicines.
For the full list of all side effects reported Nicotine Gum, see section 4 of the package leaflets available
on the MHRA website.
Why was Nicotine Gum approved?
It was concluded that, in accordance with EU requirements, Nicotine Gum has been shown to have
comparable quality and to be bioequivalent to Nicorette 2 mg and 4 mg Freshmint Gum. Therefore, the
MHRA decided that, as for Nicorette 2 mg and 4 mg Freshmint Gum, the benefits of Nicotine Gum is
greater than their risks and recommended that it can be approved for use.
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
4
What measures are being taken to ensure the safe and effective use of Nicotine Gum?
A risk management plan has been developed to ensure that Nicotine Gum is used as safely as possible.
Based on this plan, safety information has been included in the Summaries of Product Characteristics
and the package leaflets for Nicotine Gum, including the appropriate precautions to be followed by
healthcare professionals and patients.
Known side effects are continuously monitored. Furthermore new safety signals reported by
patients/healthcare professionals will be monitored/reviewed continuously as well.
Other information about Nicotine Gum
Marketing Authorisations were granted in the UK on 11 December 2015.
The full PAR for Nicotine Gum follows this summary.
For more information about treatment with Nicotine Gum, read the package leaflets, or contact your
doctor or pharmacist.
This summary was last updated in January 2016.
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
5
TABLE OF CONTENTS
I Introduction Page 6
II Quality aspects Page 7
III Non-clinical aspects Page 8
IV Clinical aspects Page 9
V User consultation Page 12
VI Overall conclusion, benefit/risk assessment and
recommendation
Page 12
Table of content of the PAR update Page 17
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
6
I INTRODUCTION
Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products
Regulatory Agency (MHRA) granted Wrafton Laboratories Limited, Marketing Authorisations for the
medicinal products Galpharm Nicotine Replace 2 mg and 4 mg Gum (PL 12063/0133-0134) on 11
December 2015.
These products are available as General sale List (GSL) medicines and are indicated for the relief and/or
prevention of nicotine withdrawal symptoms including cravings associated with smoking cessation. It is
indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling
or unable to smoke, and as a safer alternative to smoking for smokers and those around them. Nicotine 2
mg and 4 mg Gum are indicated in pregnant and lactating women making a quit attempt.
The applications were submitted under Article 10(1) of Directive 2001/83/EC, as amended, cross-
referring to Nicorette Freshmint 2 mg and 4 mg Freshmint Gum, PL 15513/0173-0174, (McNeil Products
Ltd), which were first authorised in the UK on 12 February 1996. The German reference product has
also been used in the bioequivalence studies.
The pharmacological effects of nicotine are well documented. Those resulting from chewing Nicotine 2
mg and 4 mg Gum are comparatively small. The response at any one time represents a summation of
stimulant and depressant actions from direct, reflex and chemical mediator influences on several organs.
The main pharmacological actions are central stimulation and/or depression; transient hyperpnoea;
peripheral vasoconstriction (usually associated with a rise in systolic pressure); suppression of appetite
and stimulation of peristalsis.
Increased appetite is a recognised symptom of nicotine withdrawal and post-cessation weight gain is
common. Clinical trials have demonstrated that Nicotine Replacement Therapy can help control weight
following a quit attempt.
Two bioequivalence studies were submitted to support these applications comparing the applicant’s test
products Nicotine 2 mg and 4 mg Mint Gum (Fertin Pharma S.A) with the reference products, Nicorette
2 mg and 4 mg Freshmint Gum (McNeil Consumer Healthcare GmbH, Germany) in human smoker
subjects under fasting conditions. The applicant has stated that the bioequivalence studies were
conducted in compliance with Good Clinical Practice (GCP) requirements.
With the exception of the bioequivalence studies, no new non-clinical or clinical data were submitted,
which is acceptable given that these applications were based on being generic medicinal products of the
originator products that have been in clinical use for over 10 years.
No new or unexpected safety concerns arose during the review of information provided by the
Marketing Authorisation Holder and it was, therefore, judged that the benefits of taking Galpharm
Nicotine Replace 2 mg and 4 mg Gum outweigh the risks and Marketing Authorisations were granted.
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
7
II QUALITY ASPECTS
II.1 Introduction
Each piece of chewing gum contains 2 mg or 4 mg nicotine, equivalent to 13.2 mg and 26.5 mg nicotine
resinate respectively, as active ingredient. The excipients present are gum base (containing butylated
hydroxytoluene [E321]), calcium carbonate, xylitol, sodium carbonate anhydrous, acesulfame
potassium, sucralose, peppermint, coolmix, L-menthol, talc, maltitol (E965), titanium dioxide, maltitol
liquid, carnauba wax and sodium hydrogen carbonate (2mg strength only).
All excipients comply with their respective European Pharmacopoeia monographs with the exception of
gum base, peppermint, L-menthol and coolmix which comply with satisfactory in-house specifications.
Satisfactory Certificates of Analysis have been provided for all excipients.
The chewing gums are packed in blisters with 10 or 12 pieces of chewing gum per blister. The blister
pack is made of polyvinylchloride (PVC)/polyvinyldichloride (PVdC) thermoformed blister cards,
sealed with aluminium foil. The pack sizes are 10, 12, 20, 24, 30, 36, 48, 50, 80, 96 and 108 pieces of
chewing gum. Not all pack sizes may be marketed.
Satisfactory specifications and Certificates of Analysis have been provided for all packaging
components.
II.2. Drug Substance
INN: Nicotine Resinate
Chemical name(s): 2-propenoic acid, 2-methyl-, polymer with divinylbenzene, complex with 1-
methyl-2-(3-pyridyl) pyrrolidine
Metacrylic acid polymer with divinylbenzene, complex with nicotine-S-3-(1-
methyl-2-pyrrolidinyl) pyridine.
Structural formula:
Nicotine and ion exchange resin is a complex with the following structure:
Molecular formula: C10H14N2 (C4H6O2)X (C10H10)Y
Appearance: white to slightly yellowish powder, hygroscopic
Solubility: Nicotine resinate is practically insoluble in water, but nicotine is released from the
complex, when suspended in water with cations.
Nicotine resinate is the subject of a European Pharmacopoeia monograph.
All aspects of the manufacture and control of the active substance, nicotine resinate, are covered by a
European Directorate for the Quality of Medicines and Healthcare (EDQM) Certificate of Suitability.
II.3. Medicinal Product
Pharmaceutical Development
The objective of the development programme was to formulate safe, efficacious medicated chewing gum
containing 2 mg and 4 mg nicotine resinate that are bioequivalent to the reference products Nicorette 2
mg and 4 mg Freshmint Gum (McNeil Products Ltd).
A satisfactory account of the pharmaceutical development has been provided.
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
8
Comparative in-vitro dissolution profiles have been provided for the proposed and originator products.
Manufacture of the products
Satisfactory batch formulae have been provided for the manufacture of the products, along with an
appropriate account of the manufacturing processes. The manufacturing process has been validated and
has shown satisfactory results. Process validation data on commercial scale batches have been provided.
The results are satisfactory.
Finished Product Specifications
The finished product specifications are acceptable. The test methods have been described and have been
adequately validated. Batch data have been provided that comply with the release specifications.
Certificates of Analysis have been provided for all working standards used.
Stability of the Products
Finished product stability studies were performed in accordance with current guidelines on batches of
finished product in the packaging proposed for marketing. The data from these studies support a shelf-
life of 30 months with a storage condition ‘Do not store above 25ºC’ and ‘Keep blister in outer carton to
protect from light’.
Suitable post approval stability commitments have been provided to continue stability testing on batches
of finished product.
II.4 Discussion on chemical, pharmaceutical and biological aspects
There are no objections to the approval of these applications from a pharmaceutical point of view.
III NON-CLINICAL ASPECTS
III.1 Introduction
As the pharmacodynamic, pharmacokinetic and toxicological properties of nicotine resinate are
well-known, no new non-clinical studies are required and none have been provided. An overview based
on the literature review is, thus, appropriate.
The applicant’s non-clinical expert report has been written by an appropriately qualified person and is
satisfactory, providing an appropriate review of the relevant non-clinical pharmacology,
pharmacokinetics and toxicology.
III.2 Pharmacology
Not applicable for these product type. Refer to section ‘III.1; Introduction’ detailed above.
III.3 Pharmacokinetics
Not applicable for these product type. Refer to section ‘III.1; Introduction’ detailed above.
III.4 Toxicology
Not applicable for these product type. Refer to section ‘III.1; Introduction’ detailed above.
III.5 Environmental Risk Assessment (ERA)
Since these products are intended for generic substitution, this will not lead to an increased exposure to
the environment. An environmental risk assessment is therefore not deemed necessary.
III.6 Discussion on the non-clinical aspects
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
9
No new non-clinical studies were conducted, which is acceptable given that the applications were based
on being generic medicinal products of originator products that have been licensed for over 10 years.
There are no objections to the approval of these applications from a non-clinical point of view.
IV CLINICAL ASPECTS
IV.1 Introduction
The clinical pharmacology of nicotine resinate is well-known. With the exception of data from the
bioequivalence studies detailed below, no new pharmacodynamic or pharmacokinetic data are provided
and none are required for these applications.
No new efficacy or safety studies have been performed and none are required for this type of
applications. A comprehensive review of the published literature has been provided by the applicant,
citing the well-established clinical pharmacology, efficacy and safety of nicotine resinate.
IV.2 Pharmacokinetics
In support of these applications, the applicant has submitted two bioequivalence studies under fasting
conditions comparing the test products Nicotine Peppermint 2 mg and 4 mg medicated chewing gum
(Fertin Pharma A/S which are equivalent to Galpharm Nicotine Replace 2 mg Gum, with the
reference products, Nicorette 2 mg Freshmint medicated chewing gum (McNeil Consumer
Healthcare GmbH, Germany).
Study 1
This was an open label, single dose, randomised, two period, two sequence, cross-over
bioequivalence study comparing the pharmacokinetics of the applicant’s test product Nicotine
Peppermint 2 mg medicated chewing gum (Fertin Pharma A/S), versus the reference product,
Nicorette 2 mg Freshmint medicated chewing gum (McNeil Consumer Healthcare GmbH,
Germany), in 54 healthy adult smokers under fasting conditions.
Following dosing, chewed gum cuds were collected to be analysed. For each subject a total of 19 blood
samples were collected from the start of chewing (dosing) over the following 24 hours. Samples were
collected at 5 minutes, 10 minutes and 15 minutes before dosing and at 5 minutes, 10 minutes, 20
minutes and 30 minutes, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 3.00, 6.00, 9.00, 12.00, 16.00 and 24.00 hours
post dose during both periods. Post-dose, 4 readings of exhaled carbon monoxide level measurement and
oral cavity examination were taken as per randomisation. The two treatment days were separated by a
washout period of 9 days.
Results
Ratio and 90% Confidence Intervals of Test versus Reference for nicotine (N=54)
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
10
Conclusion
The 90% confidence intervals for Cmax and AUC were within the acceptance criteria of 80.00-125.00%.
Bioequivalence has been shown for the test formulation (Nicotine Peppermint 2 mg medicated chewing
gum) and the reference formulation (Nicorette 2 mg Freshmint medicated chewing gum) under fasting
conditions.
Study 2
This was an open label, single dose, randomised, two period, two sequence, cross-over
bioequivalence study comparing the pharmacokinetics of the applicant’s test product Nicotine
Peppermint 4 mg medicated chewing gum (Fertin Pharma A/S), versus the reference product,
Nicorette 4 mg Freshmint medicated chewing gum (McNeil Consumer Healthcare GmbH,
Germany), in 40 healthy adult smokers under fasting conditions.
Following dosing, chewed gum cuds were collected to be analysed. For each subject a total of 19 blood
samples were collected from the start of chewing (dosing) over the following 24 hours. Samples were
collected at 15 minutes, 10 minutes and 5 minutes before dosing and at 5 minutes, 10 minutes, 20
minutes and 30 minutes, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 3.00, 6.00, 9.00, 12.00, 16.00 and 24.00 hours
post dose during both periods. Post-dose, 4 readings of exhaled carbon monoxide level measurement and
oral cavity examination were taken as per randomisation. The two treatment days were separated by a
washout period of 9 days.
Results
Ratio and 90% Confidence Intervals of Test versus Reference for nicotine (N=40)
Conclusion
The 90% confidence intervals for Cmax and AUC were within the acceptance criteria of 80.00-125.00%.
Bioequivalence has been shown for the test formulation (Nicotine Peppermint 4 mg medicated chewing
gum) and the reference formulation (Nicorette 4 mg Freshmint medicated chewing gum) under fasting
conditions.
IV.3 Pharmacodynamics
No new pharmacodynamic data were submitted and none were required for applications of this type.
IV.4 Clinical efficacy
No new efficacy data were submitted and none were required for applications of this type.
IV.5 Clinical safety
No new efficacy data were submitted and none were required for applications of this type.
IV.6 Risk Management Plan (RMP)
The Marketing Authorisation Holder (MAH) has submitted a risk management plan, in accordance with
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
11
the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and
interventions designed to identify, characterise, prevent or minimise risks relating to Galpharm Nicotine
Replace 2 mg and 4 mg Gum.
A summary of safety concerns and planned risk minimisation activities, as approved in the RMP,
is listed below:
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
12
IV.7 Discussion on the clinical aspects
With the exception of the bioequivalence studies, no new clinical studies were conducted, which is
acceptable given that the applications were based on being generic medicinal products of originator
products that have been licensed for over 10 years.
Bioequivalence has been demonstrated between the applicant’s products Nicotine Peppermint 2 mg and
4 mg medicated chewing gum and the reference products Nicorette 2 mg and 4 mg Freshmint medicated
chewing gum (McNeil Consumer Healthcare GmbH) under fasting conditions.
The grant of Marketing Authorisations is recommended for these applications.
V User consultation
For Galpharm Nicotine Replace 2 mg and 4 mg Gum a user consultation with target patient groups on
the package information leaflet (PIL) has been performed on the basis of a bridging report making
reference to Nicotine 4 mg Lozenges (PL 12063/0069). The bridging report submitted by the applicant is
acceptable.
VI Overall conclusion, benefit/risk assessment and recommendation
The quality of the products is acceptable, and no new non-clinical or clinical concerns have been
identified. Bioequivalence has been demonstrated between the applicant’s products and the reference
products. Extensive clinical experience with nicotine resinate is considered to have demonstrated the
therapeutic value of the compound. The benefit / risk assessment is, therefore, considered to be positive.
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
13
Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labels
In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPC) and Patient
Information Leaflets (PIL) for products granted Marketing Authorisations at a national level are
available on the MHRA website.
The approved labelling for Galpharm Nicotine Replace 2 mg and 4 mg Gum is presented below:
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
14
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
15
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
16
PAR Galpharm Nicotine Replace 2 mg and 4 mg Gum
PL 12063/0133-0134
17
Table of content of the PAR update
Steps taken after the initial procedure with an influence on the Public Assessment Report (Type II
variations, PSURs, commitment
Date
submitted
Application
type
Scope Outcome